<DOC>
	<DOCNO>NCT00321737</DOCNO>
	<brief_summary>The purpose study assess ability once-daily ( QD ) treatment dexlansoprazole modify release ( MR ) 30 mg 60 mg placebo maintain heal erosive esophagitis ( EE ) .</brief_summary>
	<brief_title>Efficacy Safety Dexlansoprazole MR Compared Placebo Maintaining Healing Subjects With Healed Erosive Esophagitis</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , multicenter , placebo-controlled , 6 month maintenance study . The study design compare efficacy safety daily dexlansoprazole MR ( 30 mg 60 mg ) placebo , maintain heal EE .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>Subjects must successfully complete Phase 3 Study TEE04084 ( NCT00251693 ) TEE04085 ( NCT00251719 ) ; heal esophageal erosion proven endoscopy . Complete healing assess change LA Esophagitis Classification grade A , B , C , D heal ( defined anything less criterion Grade A ) . The subject count healed endoscopy finding meet Grade A criterion . Use prescription nonprescription proton pump inhibitor ( PPIs ) , histamine ( H2 ) receptor antagonist , sucralfate , misoprostol , prokinetics throughout study . Use antacid ( except study supply ) throughout study . Use drug significant anticholinergic effect tricyclic stay stable dose throughout study . Chronic ( &gt; 12 dos per month ) use nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor . Need continuous anticoagulant therapy . Evidence uncontrolled systemic disease . Subjects participate either maintenance study ( TEE04086 [ NCT00255164 ] TEE04087 [ NCT00255151 ] ) . Subjects , opinion investigator , unable comply requirement study unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Erosive Esophagitis</keyword>
</DOC>